Moleculin Biotech, Inc. (MBRX) Bundle
An Overview of Moleculin Biotech, Inc. (MBRX)
General Summary of Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc. (MBRX) is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancer and other serious diseases. Founded in 2015, the company is headquartered in Houston, Texas. MBRX specializes in the development of a novel class of drugs, including its lead product candidate, Annamycin, which is aimed at treating various forms of cancer, particularly relapsed or refractory acute myeloid leukemia (AML).
As of 2024, Moleculin Biotech has made significant strides in clinical development, having advanced Annamycin through various phases of clinical trials. The company is also exploring additional drug candidates that utilize its proprietary technologies to enhance the effectiveness of cancer treatments. Current sales figures are not disclosed as the company has yet to achieve revenue from product sales, focusing instead on clinical development and securing funding for ongoing operations.
| Year | Company Founded | Headquarters | Lead Product Candidate | Focus Areas |
|---|---|---|---|---|
| 2015 | Yes | Houston, Texas | Annamycin | Cancer, Serious Diseases |
Company's Financial Performance in the Latest Financial Reports
For the three months ended September 30, 2024, Moleculin Biotech reported total operating expenses of $7.1 million, compared to $5.9 million for the same period in 2023. This increase is attributed mainly to a rise in research and development expenses, which were $4.9 million in the latest quarter, up from $3.3 million in the prior year. General and administrative expenses decreased to $2.2 million from $2.6 million year-over-year.
The net loss for the third quarter of 2024 was $10.6 million, compared to a net loss of $5.6 million in the third quarter of 2023. The loss per common share for the three months ended September 30, 2024, was $(2.85) compared to $(2.82) in the previous year. For the nine months ended September 30, 2024, the total net loss was $19.9 million, slightly higher than the $19.5 million loss reported for the same period in 2023.
| Financial Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Research & Development Expenses | $4.9 million | $3.3 million | $13.3 million | $12.9 million |
| General & Administrative Expenses | $2.2 million | $2.6 million | $6.6 million | $7.8 million |
| Net Loss | $10.6 million | $5.6 million | $19.9 million | $19.5 million |
| Loss per Share | $(2.85) | $(2.82) | $(6.83) | $(9.94) |
Introduction to Company as a Leader in the Industry
Moleculin Biotech is recognized as a leader within the biotechnology sector, particularly in the development of innovative cancer therapies. The company's unique approach leverages advanced technologies to enhance treatment efficacy while minimizing side effects. The ongoing clinical trials for Annamycin have garnered attention, positioning Moleculin as a promising contender in the fight against cancer.
As the company progresses through its clinical development phases, it continues to seek additional funding to support its operations and expand its research portfolio. With a dedicated focus on advancing its drug candidates, Moleculin Biotech aims to make a significant impact on patient outcomes in cancer treatment.
Mission Statement of Moleculin Biotech, Inc. (MBRX)
Company's Mission Statement Overview
The mission statement of Moleculin Biotech, Inc. (MBRX) serves as a guiding framework for the company's strategic direction and long-term objectives. It articulates the purpose of the organization and sets forth its commitment to innovation and patient care in the biotech sector. As of 2024, the mission statement emphasizes a commitment to developing breakthrough therapies for cancer and viral diseases, leveraging cutting-edge research and technology.
Core Component 1: Innovation
Moleculin Biotech prioritizes innovation in its approach to drug development. The company focuses on creating novel therapeutic candidates that address unmet medical needs, particularly in oncology. For instance, the company has advanced its lead product, Annamycin, through clinical trials aimed at treating relapsed or refractory acute myeloid leukemia (AML). As of September 30, 2024, the company reported a research and development expense of $13.3 million for the nine months ended, reflecting its investment in innovative drug development.
Core Component 2: Quality
The core value of quality underscores Moleculin's commitment to high standards in its research and product offerings. The company adheres to rigorous regulatory compliance and quality assurance processes throughout the drug development lifecycle. In its recent financial report, Moleculin's total operating expenses were reported at $19.998 million for the nine months ended September 30, 2024, indicating a substantial investment in maintaining quality and regulatory standards.
Core Component 3: Patient-Centric Approach
Moleculin Biotech's mission statement reflects a patient-centric approach, aiming to improve patient outcomes through transformative therapies. The company is dedicated to addressing significant health challenges faced by patients with cancer and viral diseases. The advancement of clinical trials, such as the MIRACLE trial for Annamycin, aims to enhance the therapeutic options available for patients. As of September 30, 2024, Moleculin's total assets amounted to $23.394 million, showcasing its financial capacity to support ongoing and future clinical initiatives.
| Financial Metrics | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Research and Development Expense | $4.932 million | $3.280 million | $13.274 million | $12.855 million |
| General and Administrative Expense | $2.172 million | $2.635 million | $6.629 million | $7.765 million |
| Total Operating Expenses | $7.135 million | $5.947 million | $19.998 million | $20.712 million |
| Net Loss | $(10.592) million | $(5.609) million | $(19.881) million | $(19.500) million |
| Cash and Cash Equivalents | $9.405 million | $24.579 million |
The mission statement and its core components are essential for guiding Moleculin Biotech's strategic initiatives and operational focus, fostering a culture of innovation, quality, and patient care as it navigates the competitive landscape of the biotech industry.
Vision Statement of Moleculin Biotech, Inc. (MBRX)
Vision Statement of Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc. (MBRX) aims to become a leader in the development of innovative therapies for the treatment of cancer and viral diseases. The company focuses on leveraging its proprietary technologies to enhance patient outcomes and revolutionize treatment paradigms.
Innovation in Drug DevelopmentAt the core of Moleculin's vision is a commitment to innovation in drug development. The company is advancing its lead product candidate, Annamycin, which is in clinical trials for the treatment of acute myeloid leukemia (AML). As of September 30, 2024, Moleculin reported research and development expenses of $13.3 million for the nine months ended September 30, 2024, compared to $12.9 million for the same period in 2023, indicating ongoing investment in its pipeline.
Collaboration with Leading InstitutionsMoleculin collaborates with prominent research institutions like MD Anderson Cancer Center to drive its research efforts. In the nine months ended September 30, 2024, expenses related to license agreements with MD Anderson totaled $180,000, demonstrating the strategic partnerships aimed at enhancing research capabilities.
Focus on Patient-Centric SolutionsThe company’s vision emphasizes the importance of patient-centric solutions, aiming to address unmet medical needs. As part of its strategy, Moleculin seeks to provide therapies that significantly improve the quality of life for patients suffering from serious diseases. The anticipated gross proceeds from its August 2024 offering, amounting to approximately $5.5 million before expenses, are intended to support the advancement of its drug portfolios through clinical development.
Financial Health and SustainabilityAs of September 30, 2024, Moleculin's total assets were reported at $23.4 million with total liabilities of $15.9 million, resulting in stockholders' equity of $7.5 million. The company plans to seek additional funding of approximately $15 million to support ongoing and future operations, ensuring the sustainability of its vision.
Commitment to Research and DevelopmentMoleculin's vision is underpinned by a robust commitment to research and development. The company has recognized stock-based compensation expenses for R&D amounting to $319,000 for the nine months ended September 30, 2024. This reflects the company's dedication to building a skilled workforce that can drive innovation and successful clinical outcomes.
| Financial Metrics | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Research and Development Expense | $4.9 million | $3.3 million | $1.6 million increase |
| General and Administrative Expense | $2.2 million | $2.6 million | $0.4 million decrease |
| Net Loss | $(10.6 million) | $(5.6 million) | $(5 million) increase |
| Cash and Cash Equivalents | $9.4 million | $24.6 million | Decrease of $15.2 million |
Through these strategic initiatives, Moleculin Biotech, Inc. aims to fulfill its vision of becoming a pioneering force in the biotech industry, dedicated to delivering innovative therapeutic solutions that enhance patient care and outcomes.
Core Values of Moleculin Biotech, Inc. (MBRX)
Integrity
The core value of integrity at Moleculin Biotech, Inc. (MBRX) emphasizes transparency and ethical behavior in all operations. This is crucial for maintaining trust with stakeholders, including investors, regulatory bodies, and patients.
In 2024, Moleculin Biotech has demonstrated its commitment to integrity by adhering to rigorous compliance standards in clinical trials and reporting. For example, the company has consistently reported its financial performance and operational metrics, ensuring that stakeholders have a clear view of its activities. For the three months ended September 30, 2024, MBRX reported a net loss of $10.6 million, compared to a net loss of $5.6 million in the same period in 2023.
Innovation
Innovation is a central value for Moleculin Biotech, driving the development of novel therapeutics for hard-to-treat cancers and viruses. The company focuses on leveraging its proprietary drug development platforms, resulting in several promising candidates.
In 2024, Moleculin's lead drug candidate, Annamycin, completed a Phase 2 clinical trial and is preparing for a Phase 3 trial. This advancement illustrates the company's innovative approach in addressing unmet medical needs. The investment in research and development was approximately $4.9 million for the three months ended September 30, 2024.
Collaboration
Collaboration at Moleculin Biotech involves partnerships with academic institutions, research organizations, and industry peers to enhance its drug development capabilities. Such collaborations are essential for advancing clinical trials and sharing knowledge.
In collaboration with MD Anderson Cancer Center, Moleculin has sponsored significant research initiatives, with expenses related to license agreements amounting to $63,000 for the three months ended September 30, 2024. These partnerships enable the company to utilize leading expertise and resources to propel its clinical programs forward.
Accountability
Accountability is a fundamental value that ensures Moleculin Biotech takes responsibility for its actions and decisions, particularly in financial and operational performance.
The company's financial statements reflect a commitment to accountability, as evidenced by the comprehensive reporting of its financial activities. For the nine months ended September 30, 2024, the total operating expenses were reported at $20 million, with research and development expenses constituting a significant portion. This transparency allows stakeholders to assess the company's performance against its strategic goals.
Excellence
Excellence drives Moleculin Biotech to achieve high standards in its operations, product development, and patient care. The company strives for superior outcomes in clinical trials and operational efficiencies.
In 2024, Moleculin's operational excellence was highlighted by its ability to secure gross proceeds of approximately $5.5 million from a public offering, which is being utilized to advance its drug candidates and enhance clinical development. This funding is instrumental in maintaining the company's trajectory toward achieving its strategic objectives.
| Core Value | Description | 2024 Example |
|---|---|---|
| Integrity | Transparency and ethical behavior in operations | Reported a net loss of $10.6 million for Q3 2024 |
| Innovation | Development of novel therapeutics | Annamycin completed Phase 2 trial; preparing for Phase 3 |
| Collaboration | Partnerships to enhance drug development | Sponsored research expenses of $63,000 with MD Anderson |
| Accountability | Responsibility for actions and decisions | Reported total operating expenses of $20 million for 9M 2024 |
| Excellence | High standards in operations and patient care | Secured $5.5 million in gross proceeds from a public offering |
Moleculin Biotech, Inc. (MBRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Moleculin Biotech, Inc. (MBRX) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Moleculin Biotech, Inc. (MBRX)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Moleculin Biotech, Inc. (MBRX)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.